Drug Trial Radar · NCT07401199
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Feb 5, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Qun ZhaoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shijiazhuang People's Hospital; Baoding Central Hospital; Hengshui People's Hospital; Wuhan University Affiliated People's Hospital; The Fifth Affiliated Hospital of Anhui Medical University
- First posted
- Feb 10, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy. While this approach is effective for many patients, responses vary significantly, and there are currently no reliable tools to predict which patients will benefit the most before treatment begins. The PRISM-GC study aims to develop and validate a novel Artificial Intelligence (AI) system to address this need. This is a prospective, observational study that will collect data from patients diagnosed with locally advanced gastric cancer who are scheduled to receive standard neoadjuvant chemotherapy combined with immunotherapy in a real-world clinical setting. The specific choice of immunotherapy drug is determined by the treating physician and is not dictated by the study. Researchers will analyze standard preoperative CT scans and pathological tissue slides using advanced deep learning algorithms. The goal is to create a "multimodal" AI model that can accurately predict how well a tumor will respond to treatment (specifically, whether the tumor will disappear or shrink significantly). If successful, this AI tool could help doctors personalize treatment plans in the future, ensuring that each patient receives the most effective therapy while avoiding unnecessary side effects.
Conditions
- Gastric Cancer (GC)
- Locally Advanced Gastric Cancer
Interventions
Standard of Care PD-1 InhibitorsDrug
Patients receive standard neoadjuvant chemotherapy (e.g., SOX or XELOX regimen) combined with any NMPA-approved PD-1 inhibitor (including but not limited to Sintilimab, Tislelizumab, Camrelizumab, etc.) as determined by the treating physician in real-world practice.
Multimodal AI AssessmentDiagnostic test
Non-invasive assessment using a multimodal deep learning system (DeepComp) to analyze preoperative contrast-enhanced CT images and pathological slides. The AI model predicts the probability of pathological complete response (pCR) but does not alter the clinical treatment plan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Predictive Accuracy of the Multimodal AI Model for Pathological Complete Response (pCR)Time frame: From baseline assessment to postoperative pathological evaluation (approximately 5 months)
- Pathological Complete Response (pCR) RateTime frame: At the time of postoperative pathological evaluation (approximately 1 month after surgery)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
The Fifth Affiliated Hospital of Anhui Medical University
Fuyang, Anhui, China · Recruiting
Cangzhou People's Hospital
Cangzhou, Hebei, China · Recruiting
Hengshui People's Hospital
Hengshui, Hebei, China · Recruiting
The Second Affiliated Hospital of Xingtai Medical College
Xingtai, Hebei, China · Recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Yichang Central Hospital
Yichang, Hubei, China · Recruiting
Baoding Central Hospital
Baoding, None Selected, China · Recruiting
Shijiazhuang People's Hospital
Shijiazhuang, None Selected, China · Recruiting
the Fourth Hospital of Hebei Medical University
Shijiazhuang, None Selected, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.